De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-6473|21|11|1395-1402

ISSN： 1527-6465

Source： LIVER TRANSPLANTATION, Vol.21, Iss.11, 2015-11, pp. : 1395-1402

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 5, 2015-05 ,pp. : 623-630

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 22, Iss. 9, 2016-09 ,pp. : 1295-1300

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hepatology: De novo primary sclerosing cholangitis post liver transplantation

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1114-1114

John Wiley & Sons Inc

Access to resources Recommend Favorite

PNPLA3 as a liver steatosis risk factor following living‐donor liver transplantation for hepatitis C

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E335-E339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 7, 2015-07 ,pp. : 1843-1854

John Wiley & Sons Inc

Access to resources Recommend Favorite